Nachrichten zur Atai Beckley N.V. Aktie

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said its registered underwritten offering of approximately 26.2 million shares will be priced at $2.10…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced a proposed underwritten public offering of $55 million of its common shares. The…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr. Srinivas Rao joined Proactive to discuss promising results from Beckley Psytech’s Phase 2a…

…

Positive data from Irish biotechnology firm GH Research’s Phase 2 trial of GH001, an inhalation formulation of synthetic mebufotenin (5-MeO-DMT),…

…

atai Life Sciences could create value in the near-term with the release of key Phase 2 and 3 datasets for…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline results from Beckley Psytech’s Phase 2a study of BPL-003 (intranasal 5-MeO-DMT...…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced several key leadership appointments to advance its aim of delivering innovative mental health...…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares should move higher on a slew of Phase 2 and 3 data readouts in…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC), a biopharmaceutical company targeting mental health disorders, advanced its pipeline of innovative therapies...…

…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC)’ chief scientific officer Dr Srinivas Rao joined Proactive to discuss the companys latest clinical trial…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has been awarded a Buy rating from Jefferies analysts as the company’s pipeline of mental health therapies...…

…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has provided an update on its research activities and told investors it has cash, marketable…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) recently welcomed encouraging results from Beckley Pystech’s Phase 1 trial of its patient-protected intravenous...…

…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has welcomed promising initial results from Beckley Psytech’s Phase1 trial of its patient-protected intravenous...…

Analysts at Jefferies remain bullish on atai Life Sciences (NASDAQ:ATAI, ETR:9VC) as the broader psychedelic space this week hit a “technical…

atai Life Sciences has announced the appointments of Scott Braunstein and Laurent Fischer as directors to its board. Braunstein previously…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has a pipeline of psychedelic and non-psychedelic drug assets that are poised to create value,…

Deep Dive - atai Life Sciences…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced co-founder Srinivas Rao will take on the CEO role following the resignation of…

atai Life Sciences has announced Florian Brand will step down as chief executive and be succeeded by co-founder Srinivas Rao.…

atai Life Sciences has announced Florian Brand will step down as chief executive and be succeeded by co-founder Srinivas Rao.…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that Beckley Psytech has dosed the first patient in the second part of its…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the results of investee Beckley Beckley Psytechs Phase 1 study of its novel,…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) made significant strides in advancing its innovative mental health therapies in 2023, with a focus…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) made significant strides in advancing its innovative mental health therapies in 2023, with a focus…

…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it has enough cash, marketable securities, and a committed loan facility to support its…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has hailed positive results from its investee Beckley Psytech’s Phase 2a study of its novel…

…

SAINT LAURENT, Quebec, March 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company”) announces that…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first healthy participant in a Phase 1b trial evaluating its…

^* Mehrere Wirkstoffe im fortgeschrittenen klinischen Stadium der Entwicklung, einschließlich der laufenden Phase-2b-Studie…

^NEW YORK und BERLIN, Aug. 09, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (?atai"), ein…

^NEW YORK und BERLIN, June 05, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (https://www.globenewswire.com/Tracker?data=UNr9qaj0f07x0v0u3EnbnPbmJOmc- XY7cNzpZfvDcF-iMshPifzuiY7QD0BaEaMCWxG7MSHGfU1IgWlaVkrUJCVs_IhUy- t0B7zHHSmqOwJFyhPE7qWYlzNrah2Ba2NkRa0lkGMN83dC0WHO_nFU1csu- 4TP8Z5FxRCA3w1ZQpvQSlC9uwIsXspZ- krW0q7O1LIFN_ZYyV2D2gnCG1naG6yiAKRTuQoq4apOQDHPCOo=) (NASDAQ: ATAI) (?atai"), ein…

^* RL-007: Erster Patient in der Phase-IIb-Studie zu RL-007 bei kognitiver Beeinträchtigung im…

^NEW YORK und BERLIN, May 03, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (https://www.globenewswire.com/Tracker?data=UNr9qaj0f07x0v0u3EnbnPbmJOmc- XY7cNzpZfvDcF-iMshPifzuiY7QD0BaEaMCWxG7MSHGfU1IgWlaVkrUJCVs_IhUy- t0B7zHHSmqOwJFyhPE7qWYlzNrah2Ba2NkRa0lkGMN83dC0WHO_nFU1csu- 4TP8Z5FxRCA3w1ZQpvQSlC9uwIsXspZ- krW0q7O1LIFN_ZYyV2D2gnCG1naG6yiAKRTuQoq4apOQDHPCOo=) (NASDAQ: ATAI) (?atai"), ein…

^NEW YORK und BERLIN, May 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (https://www.globenewswire.com/Tracker?data=UNr9qaj0f07x0v0u3EnbnPbmJOmc- XY7cNzpZfvDcF-iMshPifzuiY7QD0BaEaMCWxG7MSHGfU1IgWlaVkrUJCVs_IhUy- t0B7zHHSmqOwJFyhPE7qWYlzNrah2Ba2NkRa0lkGMN83dC0WHO_nFU1csu- 4TP8Z5FxRCA3w1ZQpvQSlC9uwIsXspZ- krW0q7O1LIFN_ZYyV2D2gnCG1naG6yiAKRTuQoq4apOQDHPCOo=) (NASDAQ: ATAI) (?atai"), ein…

^NEW YORK und BERLIN, April 17, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (https://www.globenewswire.com/Tracker?data=UNr9qaj0f07x0v0u3EnbnPbmJOmc- XY7cNzpZfvDcF-iMshPifzuiY7QD0BaEaMCWxG7MSHGfU1IgWlaVkrUJCVs_IhUy- t0B7zHHSmqOwJFyhPE7qWYlzNrah2Ba2NkRa0lkGMN83dC0WHO_nFU1csu- 4TP8Z5FxRCA3w1ZQpvQSlC9uwIsXspZ- krW0q7O1LIFN_ZYyV2D2gnCG1naG6yiAKRTuQoq4apOQDHPCOo=) (NASDAQ: ATAI) (?atai"), ein…

^* Die Entwicklungskandidaten von atai, wie RL-007 und GRX-917, stellen allesamt bedeutende Möglichkeiten…

^* RL-007: Erster Patient in der laufenden Phase-2b-Studie bei kognitiver Beeinträchtigung im Zusammenhang…

^NEW YORK und BERLIN, March 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (https://www.globenewswire.com/Tracker?data=UNr9qaj0f07x0v0u3EnbnPbmJOmc- XY7cNzpZfvDcF-iMshPifzuiY7QD0BaEaMCWxG7MSHGfU1IgWlaVkrUJCVs_IhUy- t0B7zHHSmqOwJFyhPE7qWYlzNrah2Ba2NkRa0lkGMN83dC0WHO_nFU1csu- 4TP8Z5FxRCA3w1ZQpvQSlC9uwIsXspZ- krW0q7O1LIFN_ZYyV2D2gnCG1naG6yiAKRTuQoq4apOQDHPCOo=) (NASDAQ: ATAI) (?atai"), ein…